CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Apotex Inc. v. Boehringer Ingelheim Pharmaceuticals, Inc.

1:24-cv-00577

Overview

Case Number 1:24-cv-00577
Filing Date 2024-05-13
Status Terminated
Termination Date 2025-02-28
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:1 Patent Infringement
Jury Demand None

Parties

Defendant

Boehringer Ingelheim Pharma GmbH & Co. KG Operating Company

Represented By

1 Attorneys Listed

Jeremy A. Tigan

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9106

1201 North Market Street, P.O. Box 1347

Boehringer Ingelheim International GmbH Operating Company

Represented By

1 Attorneys Listed

Jeremy A. Tigan

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9106

1201 North Market Street, P.O. Box 1347

Boehringer Ingelheim Pharmaceuticals, Inc. Operating Company

Represented By

1 Attorneys Listed

Jeremy A. Tigan

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9106

1201 North Market Street, P.O. Box 1347

Plaintiff

Apotex Inc. Operating Company

Represented By

3 Attorneys Listed

Aaron M. Johnson

Email: ajohnson@taftlaw.com

Megan C. Haney

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, McLaughlin & Hall, P.A., DE

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 6 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (6): πŸ‡ͺπŸ‡Ί Europe πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9907756
Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Filed: 2016-07-07
Issued: 2018-03-06
Active (2.5 yrs remaining)
Expires: 2029-06-07
US10105323
Pharmaceutical dosage form for immediate release of an indolinone derivative
Filed: 2017-05-09
Issued: 2018-10-23
Active (10.5 yrs remaining)
Expires: 2037-05-09

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

19

Dispositive

0

Granted

0

Denied

0

Pending / Review

11

Motions by Category

Procedural / Extension Motion 19

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Defendants to move, answer or otherwise respond to the Complaint to February 28, 2025 - filed by Apotex Inc.. (Haney, Megan) (Ent...
Entry #21 • 2025-02-05 Document →
Procedural / Extension Motion Pending
SO ORDERED re 21 STIPULATION TO EXTEND TIME for Defendants to move, answer or otherwise respond to the Complaint to February 28, 2025 (Set/Reset Answer Deadline...
Entry #β€” • 2025-02-05
Procedural / Extension Motion Pending
SO ORDERED re 20 STIPULATION TO EXTEND TIME for Defendants Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, and Boehringer In...
Entry #β€” • 2025-01-31
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Defendants Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, and Boehringer Ingelheim Pharma Gm...
Entry #20 • 2025-01-30 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Defendants Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, and Boehringer Ingelheim Pharma Gm...
Entry #19 • 2025-01-14 Document →
Procedural / Extension Motion Pending
SO ORDERED re 19 STIPULATION TO EXTEND TIME for Defendants Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, and Boehringer In...
Entry #β€” • 2025-01-14

Docket Entries

(52 total)
Procedural / Extension Motion Pending / Under Review

MOTION for Leave to file Complaint and Exhibits Under Seal - filed by Apotex Inc. (Attachments: # 1 Exhibit A, # 2 Proposed Order)(mrr) (Entered: 05/14/2024)

Entry #1 • 2024-05-13
1
Pleading / Complaint

[SEALED] COMPLAINT filed for Declaratory Judgment of Patent Non-Infringement against Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc. (Filing fee $ 405, receipt number ADEDC-4405910.) - filed by Apotex Inc. (Attachments: # 1 Exhibit E, # 2 Exhibit M)(mrr) (Entered: 05/14/2024)

Entry #2 • 2024-05-13
1
Pleading / Complaint

EXHIBITS re: 2 Complaint, by Apotex Inc. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit N, # 12 Exhibit O, # 13 Exhibit P, # 14 Exhibit Q, # 15 Exhibit R, # 16 Exhibit S, # 17 Exhibit T, # 18 Civil Cover Sheet)(mrr) (Entered: 05/14/2024)

Entry #3 • 2024-05-13
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mrr) (Entered: 05/14/2024)

Entry #4 • 2024-05-13
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 03/15/2024. Date of Expiration of Patent: U.S. Patent No. 9,907,756 expires on 06/07/2029, U.S. Patent No. 10,105,323 expires on 06/04/2029. Thirty Month Stay Deadline - Not applicable. Declaratory Judgment Matter(mrr) Modified on 8/15/2024 (dlw). (Entered: 05/14/2024)

Entry #5 • 2024-05-13
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc